Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression

Area of Science:

• Immunology
• Virology
• Molecular Biology

Background:

• Chemokine RANTES and its receptor CCR5 play roles in HIV-1 entry.
• N-terminal modifications of RANTES can enhance its anti-HIV-1 activity.
• CCR5 polymorphisms influence HIV-1 susceptibility and disease progression.

Purpose of the Study:

• To compare the efficacy of modified RANTES derivatives in blocking HIV-1 infection.
• To investigate the mechanisms of anti-HIV activity, focusing on CCR5 internalization and reexpression dynamics.
• To assess the impact of CCR5 gene polymorphisms on CCR5 receptor behavior upon NNY-RANTES exposure.

Main Methods:

• Utilizing modified RANTES compounds, including n-nonanoyl (NNY)-RANTES and aminooxypentane (AOP)-RANTES.
• Employing CD4(+) T cells from donors with diverse CCR5 gene polymorphisms.
• Quantifying CCR5 receptor internalization and reexpression rates using flow cytometry or similar techniques.

Main Results:

• NNY-RANTES demonstrated superior CCR5 internalization and slower reexpression compared to AOP-RANTES and native RANTES.
• CCR5 polymorphisms significantly modulated the receptor reexpression rate following NNY-RANTES treatment.
• These findings suggest receptor sequestration as a key mechanism for NNY-RANTES' anti-HIV-1 action.

Conclusions:

• N-terminal RANTES modifications represent a promising strategy for developing novel anti-HIV-1 therapeutics.
• CCR5 receptor dynamics, influenced by genetic variations, are critical in determining the effectiveness of these agents.
• Understanding CCR5 genotypes may aid in predicting HIV-1 disease progression and therapeutic responses.